Vivek Subbiah
Vivek Subbiah
Recent hallmarks of cancer iterations1 posit that durable control requires mechanism-guided co-targeting of hallmark capabilities rather than single-pathway inhibition. Translating this systems-level precision oncology framework at scale re...
Roberto Fernandes Branco
Roberto Fernandes Branco
Maria Manuela Estevinho,Iago Rodríguez-Lago,Sophie Restellini et al.
Maria Manuela Estevinho et al.
There has been much interest in the potential role of diet as a therapeutic option in Crohn's disease (CD). Several recent dietary clinical trials have been reported in "mild" Crohn's disease. Herein, we highlight several methodological pit...
David Hsiehchen,Amit G Singal
David Hsiehchen
Ongoing trials for hepatocellular carcinoma (HCC) screening and treatment have the potential to transform management. Screening trials are comparing novel imaging and blood-based strategies versus abdominal ultrasound for early HCC detectio...
Zhaohui Liao Arter,Ross A Soo
Zhaohui Liao Arter
The SACHI trial demonstrated that savolitinib plus osimertinib nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) in patients with EGFR-mutated, MET-amplified non-small-cell lun...
Deep multi-omics profiling reveals three molecular subtypes of chronic obstructive pulmonary disease in a unique biomass-exposed Chinese population [0.03%]
深度多组学分析揭示了一种独特的中国生物质暴露慢性阻塞性肺病患者群体的三种分子亚型
Wenqian Wu,Minyu Zhou,Junye Chen et al.
Wenqian Wu et al.
Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide. COPD is characterized by progressive airflow restriction and wide-spectrum heterogeneity across clinical manifestati...
Precise and efficient DNA base editing restores normal hearing in adult DFNB9 mouse model [0.03%]
精确高效的DNA单碱基编辑技术成功治疗遗传性聋小鼠模型
Ziyu Zhang,Man Wang,Fangzhi Tan et al.
Ziyu Zhang et al.
Background: Mutations in the OTOF gene, which cause autosomal recessive non-syndromic hearing loss, DFNB9, are a leading cause of auditory neuropathy. Gene augmentation and RNA and DNA editing have been used to restore th...
T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications [0.03%]
双特异性和三特异性T细胞活化剂治疗血液系统恶性肿瘤中的T细胞耗竭：机制和影响
Amelie Muth,Alessandra Holzem,Anne-Sophie Neumann et al.
Amelie Muth et al.
T cell engagers (TCEs) have revolutionized the treatment of hematologic malignancies, with eight approved bispecific constructs and numerous bi- and trispecific TCEs currently in clinical trials. However, despite their clinical success, lac...
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy [0.03%]
重症肌无力难治患者接受自体CD19/BCMA双靶点CAR-T细胞治疗的免疫重塑的单细胞分析
Zhe Ruan,Fan Ning,Wenyan Zhang et al.
Zhe Ruan et al.
Background: Chimeric antigen receptor (CAR) T cells targeting CD19 or B cell maturation antigen (BCMA) hold great promise to treat neuroimmune disorders, but the efficacy of CD19/BCMA dual-targeting CAR-T cells and their ...
A machine learning model integrating circulating Temra cell transcriptional profiles to predict immunotherapy efficacy [0.03%]
一种整合循环Temra细胞转录组谱预测免疫治疗疗效的机器学习模型
Yichen Dong,Xuanhao Xu,Haojie Si et al.
Yichen Dong et al.
Background: While immunotherapy has transformed treatment paradigms for cancer, durable response rates remain below 30%. Currently available biomarkers are insufficient for precise patient stratification. Blood-based biom...